Voigt, Anna Maria; Neubert, Karl; Hoh, Stella et al.
Prevalence of retinal vascular anomalies in the German population: results from the Gutenberg Health StudyINVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. Bd. 65. H. 7. 2024
Merkel, Daniel; Lueders, Christian; Schneider, Christoph et al.
Prospective Comparison of Nine Different Handheld Ultrasound (HHUS) Devices by Ultrasound Experts with Regard to B-Scan Quality, Device Handling and Software in Abdominal SonographyDIAGNOSTICS. Bd. 14. H. 17. 2024
Kommer, Andreas; Kostev, Karel; Schleicher, Eva Maria et al.
Proton pump inhibitor use and bone fractures in patients with chronic kidney diseaseNEPHROLOGY DIALYSIS TRANSPLANTATION. Bd. 40. H. 1. 2024 S. 173-181
Gairing, Simon Johannes; Mangini, Chiara; Zarantonello, Lisa et al.
Proton pump inhibitor use and risk of hepatic encephalopathy: A multicentre studyJHEP REPORTS. Bd. 6. H. 8. 2024
Gairing, Simon Johannes; Mangini, Chiara; Zarantonello, Lisa et al.
Proton pump inhibitors are not associated with an increased risk of hepatic encephalopathyJOURNAL OF HEPATOLOGY. Bd. 80. 2024 S. S211-S211
Salazar, Isaac Israel Rodriguez; Teufel, Andreas; Vellala, Abhinay et al.
RADIOMICS-BASED PREDICTION OF HCC RESPONSE TO ATEZOLIZUMAB/BEVACIZUMABHEPATOLOGY. Bd. 80. 2024
Buonfiglio, Francesco; Ponto, Katharina A.; Pfeiffer, Norbert et al.
Redox mechanisms in autoimmune thyroid eye diseaseAUTOIMMUNITY REVIEWS. Bd. 23. H. 5. 2024
Holch, Julian Walter; Ohnmacht, Alexander; Stintzing, Sebastian et al.
Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).JOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 3_SUPPL. 2024 S. 13-13
Toyoda, Hidenori; Kanneganti, Mounika; Melendez-Torres, Jonathan et al.
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular CarcinomaCLINICAL GASTROENTEROLOGY AND HEPATOLOGY. Bd. 22. H. 1. 2024
Galle, Peter Robert; Kudo, Masatoshi; Llovet, Josep M. et al.
REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteriaJOURNAL OF CLINICAL ONCOLOGY. Bd. 42. H. 16. 2024